UNSPSC 51111874: Tamoxifen citrate

This classification denotes a selective estrogen receptor modulator and protein kinase c inhibitor with the molecular formula C26H29NO.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FRV7310N6. European Medicines Agency schedules tamoxifen citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04672MIG. The term tamoxifen citrate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule tamoxifen citrate under HS 29221990 and SITC 51461.

As of Q4 2014, TAMOXIFEN CITRATE remains US FDA's Preferred Term for this commodity. Tamoxifen citrate bears US NLM identifiers UMLS ID C0919390 and NCI Concept Code C855. SMILES: CC/C(=C(\C1CCCCC1)/C2CCC(CC2)OCCN(C)C)/C3CCCCC3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51111874 Tamoxifen citrate is a Commodity code covering the procurement of this selective estrogen receptor modulator pharmaceutical, commonly used in oncology and breast cancer treatment and prevention. State and local governments purchase tamoxifen citrate primarily through health departments, corrections agencies, county and municipal healthcare facilities, and school district health clinics to support inmate healthcare, community health programs, and student wellness services. The pharmaceutical is typically procured via competitive bidding or established state and local pharmacy contracts, often bundled with broader pharmaceutical supply agreements or standalone drug tenders.

The recent state and local opportunities block provides no specific solicitations or issuing bodies for tamoxifen citrate procurement. Without posted RFP, RFQ, IFB, or ITB records naming this code, current activity levels and geographic concentration cannot be determined from available data. Firms pursuing this commodity should monitor state health department pharmaceutical contracts, county jail and prison healthcare tenders, and cooperative purchasing vehicle rosters (such as those operated by regional hospital consortia or state purchasing groups) to surface tamoxifen citrate solicitations as they emerge.